These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 8427283)

  • 1. Projecting future drug expenditures--1993.
    Santell JP
    Am J Hosp Pharm; 1993 Jan; 50(1):71-7. PubMed ID: 8427283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Projecting future drug expenditures--1992.
    Ensor PA
    Am J Hosp Pharm; 1992 Jan; 49(1):140-5. PubMed ID: 1570858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Projecting future drug expenditures--1994.
    Santell JP
    Am J Hosp Pharm; 1994 Jan; 51(2):177-87. PubMed ID: 8160668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Projecting future drug expenditures--1996.
    Santell JP
    Am J Health Syst Pharm; 1996 Jan; 53(2):139-50. PubMed ID: 8653479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
    Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
    Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Projecting future drug expenditures--2002.
    Shah ND; Vermeulen LC; Santell JP; Hunkler RJ; Hontz K
    Am J Health Syst Pharm; 2002 Jan; 59(2):131-42. PubMed ID: 11826567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Price regulation and generic competition in the pharmaceutical market.
    Dalen DM; Strøm S; Haabeth T
    Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repercussions of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Hogan GF
    Am J Hosp Pharm; 1985 Apr; 42(4):849-51. PubMed ID: 4014238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Projecting future drug expenditures--1997.
    Mehl B; Santell JP
    Am J Health Syst Pharm; 1997 Jan; 54(2):153-61. PubMed ID: 9117803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Points to consider about prescription drug prices: an overview of federal policy and pricing studies.
    Kucukarslan S; Hakim Z; Sullivan D; Taylor S; Grauer D; Haugtvedt C; Zgarrick D
    Clin Ther; 1993; 15(4):726-38. PubMed ID: 8221823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical prices continue to drive up supply costs.
    Hard R
    Hospitals; 1992 Mar; 66(5):49-50. PubMed ID: 1740289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the process of medication budget forecasting.
    Vermeulen LC; Marnocha RM; Thielke TS
    Pharm Pract Manag Q; 1998 Apr; 18(1):72-80. PubMed ID: 10177544
    [No Abstract]   [Full Text] [Related]  

  • 14. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent drug approvals from the US FDA and EMEA: what the future holds.
    Pevarello P
    Future Med Chem; 2009 Apr; 1(1):35-48. PubMed ID: 21426069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
    Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Projecting future drug expenditures--1999.
    Mehl B; Santell JP
    Am J Health Syst Pharm; 1999 Jan; 56(1):31-9. PubMed ID: 10048877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization, price, and spending trends for antidepressants in the US Medicaid Program.
    Chen Y; Kelton CM; Jing Y; Guo JJ; Li X; Patel NC
    Res Social Adm Pharm; 2008 Sep; 4(3):244-57. PubMed ID: 18794035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in manufacturer prices of brand name prescription drugs used by older Americans--first quarter 2004 update.
    Gross DJ; Schondelmeyer SW; Raetzman SO
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2004 Jun; (IB69):1-12, 1-2. PubMed ID: 15368653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.